E. Marcuello

1.4k total citations
38 papers, 1.1k citations indexed

About

E. Marcuello is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. Marcuello has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. Marcuello's work include Colorectal Cancer Treatments and Studies (21 papers), Cancer therapeutics and mechanisms (8 papers) and Gastric Cancer Management and Outcomes (8 papers). E. Marcuello is often cited by papers focused on Colorectal Cancer Treatments and Studies (21 papers), Cancer therapeutics and mechanisms (8 papers) and Gastric Cancer Management and Outcomes (8 papers). E. Marcuello collaborates with scholars based in Spain and Netherlands. E. Marcuello's co-authors include Montserrat Baiget, E. del Rı́o, Albert Altés, Anna Menoyo, Gabriel Capellá, Miguel A. Peinado, Ramón Mangues, Rosa Ana Risques, Laia Paré and Josep R. Germà and has published in prestigious journals such as Journal of Clinical Oncology, Kidney International and British Journal of Cancer.

In The Last Decade

E. Marcuello

38 papers receiving 1.1k citations

Peers

Countries citing papers authored by E. Marcuello

Since Specialization

Citations

This map shows the geographic impact of E. Marcuello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Marcuello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Marcuello more than expected).

Fields of papers citing papers by E. Marcuello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Marcuello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Marcuello. The network helps show where E. Marcuello may publish in the future.

Co-authorship network of co-authors of E. Marcuello

This figure shows the co-authorship network connecting the top 25 collaborators of E. Marcuello. A scholar is included among the top collaborators of E. Marcuello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Marcuello. E. Marcuello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer 2013 ·Clinical & Translational Oncology ·Alfredo Carrato, (unknown), P. Escudero, Manuel Chaves-Conde, Fernando Rivera, E. Marcuello, Encarnación González‐Flores, Cristina Grávalos, Manuel Constenla, José Luís Zamora Manzano, Ferrán Losa, Joan Maurel, Rosario Dueñas, Bartomeu Massutí, Javier Gállego, Jorge Aparicio, A. Antón, Enrique Aranda	7
2	A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer 2011 ·British Journal of Cancer ·E. Marcuello, David Páez, Laia Paré, Juliana Salazar, Ana Sebio, E. del Rı́o, Montserrat Baiget	84
3	UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy 2010 ·British Journal of Cancer ·Eva Martinez‐Balibrea, Albert Abad, Anna Martínez‐Cardús, Àngels Ginès, (unknown), M. Navarro, Enrique Aranda, E. Marcuello, Manuel Benavides, Bartomeu Massutí, Alfredo Carrato, Laura Layos, José Luís Zamora Manzano, Vı́ctor Moreno	72
4	Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy 2008 ·British Journal of Cancer ·Laia Paré, E. Marcuello, Albert Altés, E. del Rı́o, (unknown), Juliana Salazar, (unknown), Agustí Barnadas, Montserrat Baiget	96
5	Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study 2008 ·Annals of Oncology ·Enrique Aranda, (unknown), (unknown), Manuel Benavides, (unknown), (unknown), E. Marcuello, Manuel Constenla, Juan Carlos Cámara, Alfredo Carrato, Rosario Dueñas, Margarita Reboredo, M. Navarro, Eduardo Díaz‐Rubio	15
6	Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin? 2007 ·The Pharmacogenomics Journal ·Laia Paré, E. Marcuello, Albert Altés, E. del Rı́o, (unknown), A. Barnadas, Montserrat Baiget	9
7	K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12 2006 ·Carcinogenesis ·María Virtudes Céspedes, (unknown), (unknown), Matilde Parreño, Isolda Casanova, Miguel Ángel Pavón, E. Marcuello, Manuel Trías, Marta Cascante, Gabriel Capellá, Ramón Mangues	59
8	Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? 2005 ·Cancer Chemotherapy and Pharmacology ·E. Marcuello, Albert Altés, Anna Menoyo, E. del Rı́o, Montserrat Baiget	68
9	Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer 2004 ·Annals of Oncology ·Enrique Aranda, Alfredo Carrato, Andrés Cervantes, Javier Sastre, (unknown), (unknown), (unknown), (unknown), E. Marcuello, L. Pronk, Miquel Balcells, Eduardo Díaz‐Rubio	6
10	Biweekly irinotecan (CPT-11) plus 5-FU as first-line chemotherapy for elderly patients with metastatic colorectal cancer (MCRC). Final results of the Spanish Digestive Group (TTD) study 2004 ·Journal of Clinical Oncology ·E. Marcuello, Javier Sastre, (unknown), M. Navarro, Silvia Gil, A. Antón, Albert Abad, Eduardo Díaz‐Rubio	2
11	UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer 2004 ·British Journal of Cancer ·E. Marcuello, Albert Altés, Anna Menoyo, E. del Rı́o, (unknown), Montserrat Baiget	239
12	Management and Prognosis of Transitional Cell Carcinoma Superficial Recurrence in Muscle-Invasive Bladder Cancer after Bladder Preservation 2003 ·European Urology ·Enrique Pieras, Juan Palou, Jorge A. R. Salvador, Antonio Rosales, E. Marcuello, H. Villavicencio	11
13	Irinotecan (CPT-11) in metastatic colorectal cancer patientsresistant to 5-fluorouracil (5-FU): A phase II study 2003 ·Methods and Findings in Experimental and Clinical Pharmacology ·Andrés Antón, (unknown), Alfredo Carrato, E. Marcuello, (unknown), Andrés Cervantes, (unknown), J. Sastre, (unknown), (unknown), Eduardo Díaz‐Rubio, (unknown), Miquel Balcells	7
14	595 UGT1A1 polymorphisms correlate with adverse side effects and clinical response in metastatic colorectal cancer patients treated with irinotecan 2003 ·European Journal of Cancer Supplements ·E. Marcuello, Anna Menoyo, E. del Rı́o, (unknown), Miquel Balcells, M. Baiget	1
15	Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer 2002 ·British Journal of Cancer ·Xavier García del Muro, E. Marcuello, Josep Gumà, Luis Paz‐Ares, José A. Martínez-Climent, Joan Carles, (unknown), (unknown), Pablo Maroto, Josep R. Germà	34
16	Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer 2000 ·British Journal of Cancer ·Marta Palicio, Ignacio Blanco, Silvia Tórtola, Isabel González‐Álvarez, E. Marcuello, Joan Brunet, Fèlix Lluı́s, Juan J. González‐Aguilera, Miguel A. Peinado, Gabriel Capellá	12
17	Systemic contact dermatitis from 5–fluorouracil 1996 ·Contact Dermatitis ·(unknown), Ramón M. Pujol, (unknown), E. Marcuello, Agustı́n Alomar	9
18	Radioimmunolocalization of colorectal carcinoma. A correlation among RIL results, surgical findings, serum tumor marker levels and the presence of CEA and CA 19.9 in tumor tissue: The experience of the Hospital de la Santa Creu i Sant Pau 1991 ·Annals of Oncology ·Josep Ramón Germà-Lluch, Isabel Álvarez, Ignasi Carrió, F. Nogueras, E. Marcuello, M Estorch, L Bernà	2
19	Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer 1988 ·European Journal of Cancer and Clinical Oncology ·E. Marcuello, Emilio Alba, (unknown), (unknown), (unknown), (unknown), Cinta Pallarés, J.R. Germà, (unknown)	7
20	Incidence and outcome of malignancy in patients on dialysis program 1985 ·Kidney International ·(unknown), (unknown), E. Marcuello, J. Aubía, J Lloveras, J Masramón, (unknown), (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact